CANscript is a human, immune-relevant ex vivo platform for oncology research teams

CANscript recreates the in vivo tumor microenvironment ex vivo, maintaining the heterogeneity of the tumor while preserving its immune compartment.

Develop a solid understanding of human MOA prior to clinical trials

Define the underlying biology and modulation of your drug candidates in a live heterogeneous human tumor microenvironment before going into patients.

Prioritize advancement of your best candidates into clinical trials

Simultaneously interrogate live human tumors in multi-arm studies to eliminate of intra-cohort variability and enable head-to-head comparisons of single agents and combinations.

Increase your
clinical success

Test your drug candidates in this relevant tumor model that reflects the complexity of patients to increase your confidence and make better decisions prior to entering the clinic.

A human, predictive model.

Traditional models such as mouse models and cell lines don’t provide the entire picture and lack a strong clinical correlation.

Watch this video to see how CANscript dramatically streamlines oncology drug development by helping to answer key mechanistic questions about drug candidates and prioritize the most promising candidates for advancement into clinical trials.

Build a custom study for your molecule with CANscript.

Human. Efficient. Multiplexed.

CANscript starts with a tumor sample taken either from a biopsy or surgical resection, and a blood sample from the same donor. The tissue sample is divided into fragments that preserve the heterogeneity of the tumor, including tumor cells, immune cells, and stromal components.

The parallel sections, along with the autologous plasma, are then placed into wells coated with indication and grade-matched matrix proteins, recapitulating the tumor microenvironment.

CANscript employs a series of phenotypic endpoints into an M-score, developed from a machine learning algorithm trained and tested on thousands of patients, providing an accurate prediction of clinical response for each compound of interest.

As a result, multiple therapeutic options can be weighed simultaneously and with a high degree of accuracy, allowing researchers to understand mechanism of action and to prioritize the most promising candidates for advancement into clinical trials.

Read the Science

For more details on how CANscript works, and on how it can change the way you look at oncology drug development, see a list of our peer-reviewed publications.

Work with us.